Search Results - Hartmut Kirchner

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Time-intensified dexamethasone/cisplatin/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease

    Time-intensified dexamethasone/cisplatin/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease by Andreas Josting, Christian Rudolph, Marcel Reiser, MY Mapara, M. Sieber, Hartmut Kirchner, Bernd Dörken, Dieter K. Hossfeld, Volker Diehl, Andreas Engert

    Published 2002
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

    IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial by Jens Atzpodien, Hartmut Kirchner, H.J. Illiger, Bernd Metzner, D. Ukena, Harold C. Schott, P.-J. Funke, Martin Gramatzki, S von Jürgenson, T Wandert, T Patzelt, Martina Reitz

    Published 2001
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

    Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia by Felicitas Thol, Frédérik Damm, Katharina Wagner, Gudrun Göhring, Brigitte Schlegelberger, Dieter Hoelzer, Michael Lübbert, W. Heit, Lothar Kanz, Günter Schlimok, Aruna Raghavachar, Walter Fiedler, Hartmut Kirchner, Gerhard Heil, Michael Heuser, Jürgen Krauter, Arnold Ganser

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Incidence and Prognostic Influence of <i>DNMT3A</i> Mutations in Acute Myeloid Leukemia

    Incidence and Prognostic Influence of <i>DNMT3A</i> Mutations in Acute Myeloid Leukemia by Felicitas Thol, Frédérik Damm, Andrea Lüdeking, Claudia Winschel, Katharina Wagner, Michael Morgan, Haiyang Yun, Gudrun Göhring, Brigitte Schlegelberger, Dieter Hoelzer, Michael Lübbert, Lothar Kanz, Walter Fiedler, Hartmut Kirchner, Gerhard Heil, Jürgen Krauter, Arnold Ganser, Michael Heuser

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

    Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimm... by Jens Atzpodien, Hartmut Kirchner, Udo Jonas, Lothar Bergmann, Harold C. Schott, H. Heynemann, Paolo Fornara, S.A. Loening, Jan Roigas, Stefan C. Müller, H. Bodenstein, S. Pomer, Bernd Metzner, U. Rebmann, R. Oberneder, M. Siebels, T Wandert, T. Puchberger, Martina Reitz

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Single Nucleotide Polymorphism in the Mutational Hotspot of <i>WT1</i> Predicts a Favorable Outcome in Patients With Cytogenetically Normal Acute Myeloid Leukemia

    Single Nucleotide Polymorphism in the Mutational Hotspot of <i>WT1</i> Predicts a Favorable Outcome in Patients With Cytogenetically Normal Acute Myeloid Leukemia by Frédérik Damm, Michael Heuser, Michael Morgan, Haiyang Yun, Anika Großhennig, Gudrun Göhring, Brigitte Schlegelberger, Konstanze Döhner, Oliver G. Ottmann, Michael Lübbert, W. Heit, Lothar Kanz, Günter Schlimok, Aruna Raghavachar, Walter Fiedler, Hartmut Kirchner, Hartmut Döhner, Gerhard Heil, Arnold Ganser, Jürgen Krauter

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

    Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma by Andreas Engert, Annette Plütschow, Hans Theodor Eich, Andreas Lohri, Bernd Dörken, Peter Borchmann, Bernhard Berger, Richard Greil, Kay Willborn, Martin Wilhelm, Jürgen Debus, Michael J. Eble, Martin Sökler, Antony D. Ho, Andreas Rank, Arnold Ganser, Lorenz Trümper, Carsten Bokemeyer, Hartmut Kirchner, Jörg Schubert, Zdeněk Král, Michael Fuchs, Hans–Konrad Müller–Hermelink, Rolf‐Peter Müller, Volker Diehl

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis

    Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis by Felicitas Thol, Sabrina Klesse, L Köhler, Razif Gabdoulline, Arnold Kloos, Alessandro Liebich, Manfred Wichmann, Anuhar Chaturvedi, Jana Fabisch, Verena I. Gaidzik, Peter Paschka, Lars Bullinger, Gesine Bug, Hubert Serve, Gudrun Göhring, Brigitte Schlegelberger, Michael Lübbert, Hartmut Kirchner, Mohammed Wattad, Doris Kraemer, Bernd Hertenstein, Gerhard Heil, Walter Fiedler, J Krauter, Richard F. Schlenk, Konstanze Döhner, Hartmut Döhner, Arnold Ganser, Michael Heuser

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

    Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia by Rüdiger Hehlmann, Ute Berger, Markus Pfirrmann, H. Heimpel, Andreas Hochhaus, Joerg Hasford, Hans‐Jochem Kolb, Tanja Lahaye, Ole Maywald, Andreas Reiter, Dieter K. Hossfeld, Christoph Huber, Helmut Löffler, H. Pralle, Wolfgang Queißer, Andreas Tobler, Christoph Nerl, Max Solenthaler, Mariele Goebeler, Martin Grießhammer, Thomas H. Fischer, Stephan Kremers, Hartmut Eimermacher, Michael Pfreundschuh, Wolf‐Dietrich Hirschmann, Klaus Lechner, Barbara Waßmann, Christiane Falge, Hartmut Kirchner, Aloïs Gratwohl

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2

    Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2 by Peter Palmer, J. Vinke, Thierry Philip, Sylvie Négrier, Jens Atzpodien, Hartmut Kirchner, R. Oskam, C.R. Franks, Hans von der Maase, Nicholas Thatcher, C Jasmin, Sophie D. Fosså, Michel Symann, Lucien Israël, G Nagel, G. Stoter, C Rugarli, O Eremin, A Iacone, F. J. Cleton, Jozef Janssens, Willems, Lothar Bergmann, W. H. West, R. K. Oldham, Robert A. Dillman, Peter H. Wiernik, Charles A. Coltman, A. Raynor, James H. Doroshow, David Parkinson, E. Gallignoni, P J Guillou, Martin Gore, C.W. Keen, J. Timmons Roberts, Alexander Z. Harris, M. Fordham, P. Harper, M A Cornbleet, P Selby, Barry W. Hancock, N. Bleehan, S. J. Harland, Charles M. Rowland, Marek Ostrowski, Terry J. Hamblin, P S Veitch, M. Sokal, Paul G. Abrams, R.T.D. Oliver, H. Bodenstein, P. Czygan, PHM de Mulder, J. Wils

    Published 1992
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: